FDA puts partial hold on deuruxolitinib clinical program

3 May 2023
sunpharmabig

Indian drug major Sun Pharma Industries (BSE: 524715) dipped just 1% to 962.60 rupees, despite the company announcing a setback in the development of its newly-acquired product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia areata, an autoimmune dermatological disease – which is in late-stage development.

Following a recent submission to the US Food and Drug Administration (FDA), Sun Pharm said it had a teleconference call with the agency, regarding a pulmonary embolism (serious adverse events) occurring at the 12mg BID dose in one of the long-term open label extension (OLE) studies with deuruxolitinib.

Sun Pharma, India's largest drugmaker by revenue, acquired deuruxolitinib when it bought USA-based Concert Pharmaceuticals for $576 million earlier this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical